What is the recommended dose and infusion rate in drops per minute for intravenous immunoglobulin (Gamunex‑C or Octagam) 10 % solution for a 60‑kg pregnant woman?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 20, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Dosing and Infusion Rate for IVIg 10% (Gamunex-C or Octagam)

For a 60-kg pregnant woman requiring IVIg therapy, administer 1 g/kg (60 grams total) as a one-time dose, starting at 1 mg/kg/min (60 mg/min = 3.6 grams/hour = 36 mL/hour) and advancing to a maximum of 8 mg/kg/min (480 mg/min = 28.8 grams/hour = 288 mL/hour) if tolerated.

Dose Calculation

Both ASH guidelines 1, 2 and FDA labeling 3 recommend:

  • Initial dose: 1 g/kg as a one-time dose (may be repeated if necessary)
  • For 60 kg patient: 60 grams total
  • Volume needed: 600 mL (since both products are 10% = 0.1 g/mL)

Infusion Rate Protocol

For Gamunex-C 10% 3:

Starting rate: 1 mg/kg/min = 60 mg/min for this patient

  • Convert to mL/min: 60 mg/min ÷ 100 mg/mL = 0.6 mL/min = 36 mL/hour
  • Drops per minute: Using standard IV tubing (20 drops/mL): 12 drops/minute

Maximum rate (if tolerated): 8 mg/kg/min = 480 mg/min

  • Convert to mL/min: 480 mg/min ÷ 100 mg/mL = 4.8 mL/min = 288 mL/hour
  • Drops per minute: 96 drops/minute

For Octagam 10% 4:

Tiered escalation protocol:

  • First 30 minutes: 0.5 mg/kg/min = 30 mg/min = 0.3 mL/min = 18 mL/hour = 6 drops/minute
  • Next 30 minutes: 1.0 mg/kg/min = 60 mg/min = 0.6 mL/min = 36 mL/hour = 12 drops/minute
  • Next 30 minutes: 2.0 mg/kg/min = 120 mg/min = 1.2 mL/min = 72 mL/hour = 24 drops/minute
  • Maximum rate: 3.33 mg/kg/min = 200 mg/min = 2.0 mL/min = 120 mL/hour = 40 drops/minute

Critical Safety Considerations for Pregnancy

Pregnancy-Specific Dosing

Research demonstrates that weight-adjusted dosing should be maintained throughout pregnancy 5. The pharmacokinetic study showed no significant difference in drug exposure (AUC) between pre-pregnancy and first/second trimesters when using weight-adjusted dosing, supporting the standard 1 g/kg dose without modification for pregnancy.

Infusion Rate Precautions

  • Start conservatively in pregnant patients due to increased plasma volume and cardiovascular changes
  • Monitor closely for volume overload 3
  • Pregnant women are NOT at baseline increased risk for renal dysfunction from IVIg, but ensure adequate hydration before infusion 3
  • Research shows higher infusion rates (up to 0.14 mL/kg/min for Gamunex-C) are well-tolerated even in ITP patients 6, 7, but pregnancy warrants cautious escalation

Common Pitfalls to Avoid

  1. Do NOT administer subcutaneously in pregnant women with ITP—risk of hematoma formation 3
  2. Do NOT dilute either product 4
  3. Do NOT freeze or use previously frozen product 3, 4
  4. Slow or stop infusion if adverse reactions occur (most commonly headache) 3, 6
  5. Ensure product is at room temperature before administration 4

Practical Administration Summary

For 60-kg pregnant woman:

  • Total dose: 60 grams (600 mL of 10% solution)
  • Start: 36 mL/hour (12 drops/min with standard tubing)
  • Advance if tolerated: Up to 288 mL/hour for Gamunex-C or 120 mL/hour for Octagam
  • Minimum infusion time: Approximately 2-3 hours at maximum tolerated rate
  • May repeat dose if platelet response inadequate 1, 2

The evidence strongly supports IVIg use in pregnant women requiring treatment for ITP or other approved indications 1, 2, 8, with the same dosing as non-pregnant patients but with careful attention to infusion rate tolerance.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.